Catafau Ana M, Pérez Víctor, Penengo María M, Bullich Santiago, Danús Mónica, Puigdemont Dolors, Pascual Juan C, Corripio Iluminada, Llop Jordi, Perich Javier, Alvarez Enric
Centre for Imaging in Psychiatry, CRC-Mar, Hospital del Mar, Barcelona, Spain.
J Nucl Med. 2005 Aug;46(8):1301-9.
(123)I-ADAM (2-([2-([dimethylamino]methyl)phenyl]thio)-5-(123)I-iodophenylamine) has been recently proposed as a new serotonin transporter (SERT) ligand for SPECT. The objective of this study was to characterize (123)I-ADAM in healthy volunteers. (123)I-ADAM distribution in the normal brain, pseudoequilibrium interval after a single injection, normal specific uptake values, and long-term test-retest variability and reliability were investigated.
Ten healthy volunteers underwent 2 SPECT sessions under the same conditions 47.6 +/- 24.0 d apart. Scans were sequentially acquired from the time of (123)I-ADAM intravenous injection up to 12 h after injection. Regions of interest (ROIs) for cerebellum (C), midbrain, thalamus, striatum, mesial temporal region, and cortex were drawn on MR images and pasted to corresponding SPECT slices after coregistration. Specific uptake ratios (SURs) at pseudoequilibrium and the simplified reference tissue model (SRTM) methods were used for quantification. SURs were obtained as ([region - C]/C) at each time point. Test-retest variability and reliability (intraclass correlation coefficient [ICC]) were calculated.
The highest (123)I-ADAM specific uptake was found in the midbrain and thalamus, followed by the striatum and mesial temporal region. Quantification results using SUR and SRTM were correlated with R = 0.93 (test) and R = 0.94 (retest). SURs remained stable in all regions from 4 to 6 h after injection. Using SUR, test-retest variability/ICC were 13% +/- 11%/0.74 in midbrain, 16% +/- 13%/0.63 in thalamus, 19% +/- 18%/0.62 in striatum, and 22% +/- 19%/0.05 in mesial temporal region.
(123)I-ADAM accumulates in cerebral regions with high known SERT density. The optimal imaging time for (123)I-ADAM SPECT quantification is suggested to be from 4 to 6 h after a single injection. Long-term test-retest variability and reliability found in the midbrain are comparable to that reported with other (123)I-labeled SPECT ligands. These results support the use of (123)I-ADAM SPECT for SERT imaging after a single injection in humans.
（123）I-ADAM（2-（[2-（二甲基氨基甲基）苯基]硫代）-5-（123）I-碘苯胺）最近被提议作为一种用于单光子发射计算机断层扫描（SPECT）的新型5-羟色胺转运体（SERT）配体。本研究的目的是对健康志愿者体内的（123）I-ADAM进行特征描述。研究了（123）I-ADAM在正常大脑中的分布、单次注射后的伪平衡期、正常特异性摄取值以及长期重测变异性和可靠性。
10名健康志愿者在间隔47.6±24.0天的相同条件下接受2次SPECT检查。从（123）I-ADAM静脉注射时开始顺序采集扫描图像，直至注射后12小时。在磁共振成像（MR）图像上绘制小脑（C）、中脑、丘脑、纹状体、内侧颞叶区域和皮质的感兴趣区（ROI），并在配准后粘贴到相应的SPECT切片上。使用伪平衡期的特异性摄取率（SUR）和简化参考组织模型（SRTM）方法进行定量分析。在每个时间点，SUR通过（[感兴趣区 - C]/C）获得。计算重测变异性和可靠性（组内相关系数[ICC]）。
在中脑和丘脑中发现（123）I-ADAM的特异性摄取最高，其次是纹状体和内侧颞叶区域。使用SUR和SRTM的定量结果具有相关性，测试时R = 0.93，重测时R = 0.94。注射后4至6小时，所有区域的SUR保持稳定。使用SUR时，中脑的重测变异性/ICC为13%±11%/0.74，丘脑为16%±13%/0.63，纹状体为19%±18%/0.62，内侧颞叶区域为22%±19%/0.05。
（123）I-ADAM在已知SERT密度高的脑区蓄积。建议（123）I-ADAM SPECT定量分析的最佳成像时间为单次注射后4至6小时。中脑的长期重测变异性和可靠性与其他（123）I标记的SPECT配体报道的相当。这些结果支持在人体单次注射后使用（123）I-ADAM SPECT进行SERT成像。
